- Home
- REE vs NXL Comparison
REE vs NXL Comparison
Compare REE & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- NXL
- Stock Information
- Founded
- REE 2011
- NXL 2010
- Country
- REE Israel
- NXL United States
- Employees
- REE N/A
- NXL N/A
- Industry
- REE Auto Manufacturing
- NXL Medical Specialities
- Sector
- REE Consumer Discretionary
- NXL Health Care
- Exchange
- REE Nasdaq
- NXL Nasdaq
- Market Cap
- REE 22.4M
- NXL 19.3M
- IPO Year
- REE N/A
- NXL 2022
- Fundamental
- Price
- REE $0.73
- NXL $1.01
- Analyst Decision
- REE Strong Buy
- NXL Strong Buy
- Analyst Count
- REE 2
- NXL 1
- Target Price
- REE $11.75
- NXL $5.00
- AVG Volume (30 Days)
- REE 130.4K
- NXL 323.1K
- Earning Date
- REE 12-16-2025
- NXL 11-14-2025
- Dividend Yield
- REE N/A
- NXL N/A
- EPS Growth
- REE N/A
- NXL N/A
- EPS
- REE N/A
- NXL N/A
- Revenue
- REE $183,000.00
- NXL $156,931.00
- Revenue This Year
- REE $327.73
- NXL $38.28
- Revenue Next Year
- REE $36,888.82
- NXL $185.71
- P/E Ratio
- REE N/A
- NXL N/A
- Revenue Growth
- REE N/A
- NXL N/A
- 52 Week Low
- REE $0.53
- NXL $0.70
- 52 Week High
- REE $11.72
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- REE 37.44
- NXL 34.57
- Support Level
- REE $0.66
- NXL $1.01
- Resistance Level
- REE $0.99
- NXL $1.31
- Average True Range (ATR)
- REE 0.11
- NXL 0.11
- MACD
- REE -0.03
- NXL -0.05
- Stochastic Oscillator
- REE 15.61
- NXL 0.02
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.